Abstract Details

Title Development of a Patient-Reported Outcome (PRO) Instrument To Assess Complex Activities of Daily Living and Interpersonal Functioning in Patients with Mild Cognitive Impairment Due to Suspected Alzheimer's Disease: The Qualitative Research Phase

Topic Aging and Dementia

Presentation(s) P07 - (-)

Poster/Presentation
Number 133

Objective

Background BACKGROUND: Most existing outcome measures for patients on the Alzheimer's spectrum were developed to assess impairment in Alzheimer's disease (AD) and have not been validated for use in those with mild cognitive impairment (MCI) due to suspected AD. In addition, clinical assessments may lack sensitivity to detect subtle cognitive decline. The WG identified complex activities of daily living (CADL) and interpersonal functioning (IF) as areas where existing measures are not adequate.

Design/Methods DESIGN/METHODS: The WG conducted qualitative research involving semi-structured interview focus groups in patients with MCI due to suspected AD (n=25) or AD (n=40), controls (n=14), and informants (n=65). Concepts important to patients were elicited regarding their functioning. The WG and an expert panel evaluated the incorporation of these patient-generated concepts into two scales: Complex Activities of Daily Living (CADLs) and Interpersonal Functioning (IF). To document the insight of patients into their symptoms, 22 1:1 interviews with dyads (n=11 dyads) were conducted to simultaneously compare informant and patient (MCI or AD) reports about specific scenarios reflecting CADLs and IF.

Results RESULTS: During the interviews, MCI patients and informants showed concordance in describing specific concerns relevant to CADLs and IF, suggesting the reliability and validity of patient reports for these domains. This work supports the conceptual framework's core domains, CADLs and IF. The dyad interviews demonstrated that MCI patients retain insight regarding their deficits, as indicated by parallel descriptions of impairments from informants.

Conclusions CONCLUSIONS: The Cognition WG's draft PRO instrument incorporates the patient's perspective. Following demonstration of its content validity, the instrument will undergo quantitative testing to evaluate its psychometric properties.

Authors/Disclosures
Mark F. Gordon, MD, FAAN (Teva Pharmaceuticals) PRESENTER	Dr. Gordon has received personal compensation for serving as an employee of Teva. Dr. Gordon has stock in Teva.
Amy M. Duhig, PhD (Xcenda, LLC)	No disclosure on file
	No disclosure on file
	No disclosure on file
Tuyen Ong	No disclosure on file

��ɫ��

��ɫ��